S8442
SU 5416
≥98% (HPLC), powder, neuronal nitric oxide synthase inhibitor
Sinónimos:
1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one
Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C15H14N2O
Número CAS:
Peso molecular:
238.28
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
SU 5416, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
color
yellow to yellow-orange
mp
221-222 °C
solubility
DMSO: 20 mg/mL, clear (warmed), H2O: insoluble
storage temp.
−20°C
SMILES string
Cc1cc(C)c(C=C2C(=O)Nc3ccccc23)[nH]1
InChI
1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8+
InChI key
WUWDLXZGHZSWQZ-XYOKQWHBSA-N
Gene Information
human ... EGFR(1956), FLT1(2321), IGFBP1(3484), IL2(3558), KDR(3791), PDGFRB(5159)
mouse ... Flt1(14254), Kdr(16542)
General description
SU 5416 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 inhibitor. SU 5416 is known to prevent tumor growth and tumor angiogenesis. SU 5416 inhibits the activity of neuronal nitric oxide synthase and protects the neuronal cells from nitric oxide-mediated neurotoxicity. It also acts as an agonist of aryl hydrocarbon receptor and may be an effective clinical agent for treating autoimmune diseases and transplant rejection.
Application
SU 5416 has been used to treat HUVEC cells before the tube formation assay to assess its impact on the network generated from tube formation. to induce pulmonary hypertension (PH) in mice to serve as an experimental model
Biochem/physiol Actions
SU 516 inhibits the activity of neuronal nitric oxide synthase and protects the neuronal cells from nitric oxide-mediated neurotoxicity.1 It also acts an agonist of aryl hydrocarbon receptor and is an effective clinical agent for treating autoimmune diseases and transplant rejection.2
SU 5416 is a vascular endothelial growth factor (VEGF) receptor protein tyrosine kinase 1/2 inhibitor.
Features and Benefits
This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
Clase de almacenamiento
11 - Combustible Solids
ppe
dust mask type N95 (US), Eyeshields, Gloves
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Joshua D Mezrich et al.
PloS one, 7(9), e44547-e44547 (2012-09-13)
The experimental compound SU5416 went as far as Phase III clinical trials as an anticancer agent, putatively because of its activity as a VEGFR-2 inhibitor, but showed poor results. Here, we show that SU5416 is also an aryl hydrocarbon receptor
Xiaowei Nie et al.
Journal of hypertension, 35(12), 2419-2435 (2017-07-14)
Similar to cancer, pulmonary arterial hypertension (PAH) is characterized by vascular remodeling, which leads to obliteration of the small pulmonary arteriole, with marked proliferation of pulmonary artery smooth muscle cells (PASMC) and/or endothelial cells dysfunction. Aberrant expression of tumor suppressor
Loredana Ciuclan et al.
American journal of respiratory and critical care medicine, 184(10), 1171-1182 (2011-08-27)
The complex pathologies associated with severe pulmonary arterial hypertension (PAH) in humans have been a challenge to reproduce in mice due to the subtle phenotype displayed to PAH stimuli. Here we aim to develop a novel murine model of PAH